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Abstract  The  recognition  of  an  enteropathy  caused  by  olmesartan  is  recent.  It  was  ﬁrst
described in  2012  by  the  Mayo  Clinic,  which  presented  22  clinical  cases.  Olmesartan  is  a  highly
prescribed drug  and  the  differential  diagnosis  of  a  sprue-like  enteropathy  is  very  wide,  so  it  is
important  to  be  aware  of  this  pathology.
We report  a  case  of  a  67-years-old  man,  with  arterial  hypertension  under  treatment  with
olmesartan,  with  a  4-months  history  of  diarrhea  and  weight  lost.  He  was  admitted  three  times
in our  Department  during  this  period  of  time.  An  initial  diagnosis  was  made  of  lymphocytic
colitis but  he  did  not  respond  to  treatment  with  corticosteroids.  There  was  a  high  suspicion  of
celiac disease,  so  the  patient  started  a  gluten-free  diet  but  still  there  were  no  symptomatic
changes. The  patient  underwent  several  blood  and  imaging  tests  which  were  negative.  Due
to the  suspicion  of  an  enteropathy  caused  by  drugs,  olmesartan  was  stopped  and  the  patient
showed a  signiﬁcant  improvement  of  his  symptoms.
The exact  pathophysiology  of  this  entity  remains  to  be  elucidated.  It  may  affect  all  gas-
trointestinal  tract  and  mimic  a  refractory  celiac  disease  as  well  as  a  lymphocytic  colitis  due  to
similar symptoms  and  histology.  It  is  expected  more  cases  like  this  in  the  future  due  to  high  use
of olmesartan  in  current  clinical  practice.
So,  it  is  important  to  all  gastroenterologists  to  be  aware  of  this  pathology  and  take  it  into
consideration  when  putting  together  a  differential  diagnosis.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier
España, S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
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Enteropatia  por  Olmesartan
Resumo  A  enteropatia  por  Olmesartan  não  estava  reconhecida  até  ao  ano  de  2012  quando  a
‘‘Mayo Clinic’’  apresentou  22  casos.  Apesar  de  existirem  poucos  casos  publicados,  é  importante
familiarizar  os  clínicos  com  aspectos  referentes  a  esta  patologia,  visto  tratar-se  de  um  fármaco
muito prescrito  e  o  diagnóstico  diferencial  da  enteropatia  ‘‘sprue-like’’  ser  muito  amplo.
Apresentamos  o  caso  de  um  paciente  em  tratamento  com  Olmesartan  por  hipertensão  arte-
rial. É  internado  3  vezes  num  prazo  de  4  meses  por  quadro  de  diarreia  e  perda  importante  de
peso. Inicialmente,  é  diagnosticado  de  colite  linfocítica  que  não  responde  ao  tratamento  com
corticóides  e,  posteriormente,  de  provável  doenc¸a  celíaca  que  não  responde  a  dieta  sem  glúten.
Realizam-se  inúmeros  exames  complementários,  analíticos  e  de  imagem,  sem  concluir-se  nen-
hum diagnóstico.  Perante  a  suspeita  de  uma  enteropatia  por  Olmesartan,  retira-se  o  fármaco
deﬁnitivamente  e  reinicia-se  o  glúten  na  dieta,  conﬁrmando-se  uma  melhoria  espectacular  do
quadro clínico.  Durante  os  internamentos  não  tomava  Olmesartan,  sendo  o  motivo  da  melhoria
clínica durante  os  mesmos.
Os mecanismos  associados  a  esta  patologia  são  desconhecidos.  Pode  afectar  todo  o  apar-
elho digestivo  e  mimetizar  uma  doenc¸a  celíaca  refractária  e/ou  colite  linfocítica  devido  a
semelhanc¸a dos  sintomas  e  da  anatomia  patológica.  Devido  à  elevada  prescric¸ão  deste  medica-
mento, é  esperável  que  no  futuro  se  diagnostiquem  mais  casos,  motivo  pelo  qual,  os  clínicos,
principalmente  os  gastroenterologistas,  devem  de  considera-la  no  diagnóstico  diferencial.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier
España, S.L.U.  Este  é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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s1. Introduction
Sprue-like  enteropathy  is  characterized  by  diarrhea,  villous
atrophy  of  the  small  bowel  with  lymphocyte  inﬁltration,
intestinal  malabsorption,  signiﬁcant  weight  loss  and  nega-
tive  celiac  disease  serology.  This  entity  remains  a  challenge
to  all  gastroenterologists  due  to  a  wide  differential  diag-
nosis,  such  as  bacterial  overgrowth,  jejunitis,  lymphoma,
tropical  sprue,  protein-losing  enteropathy  or  immunosup-
pressive  drugs  such  as  methotrexate,  azathioprine  and
mycophenolate.1,2
Olmesartan  is  an  angiotensin  II  receptor  antagonist
indicated  for  the  treatment  of  hypertension  since  2002.
Olmesartan-associated  enteropathy  was  ﬁrst  described  in
2012  by  Rubio-Tapia  et  al.  of  the  Mayo  Clinic  when  they
reported  22  clinical  cases.1
We  describe  a  case  of  a  sprue-like  enteropathy  due  to
olmesartan  to  draw  attention  to  this  disease,  given  the  high
frequency  of  use  of  this  drug  and  the  difﬁculty  of  diagnosis
if  the  entity  it  is  not  known.
2. Case report
We  report  a  case  of  a  67-years-old  man,  with  hypertension
under  treatment  with  olmesartan  40  mg/day.  He  presented
with  a  4-months  history  of  diarrhea  and  signiﬁcant  weight
loss  of  22  kg.  He  was  hospitalised  three  times  in  our  Gas-
troenterology  Department  during  this  period  of  time.  At
ﬁrst,  the  patient  described  a  1-month  history  of  diarrhea
with  a  bowel  frequency  of  10  times/day,  mostly  by  night,
absence  of  blood  or  mucous  in  stools  and  a  weight  loss
of  7  kg.  He  had  no  abdominal  pain,  nausea,  vomiting  or
fever.  His  blood  tests  were  normal,  with  no  changes  in  his
d
l
t
7omplete  blood  cell  count,  coagulation,  ionogram,  hepatic
r  renal  function.  Stool  culture  and  Clostridium  difﬁcile
oxin  were  negative.  Colonoscopy  showed  no  macroscopic
hanges  but  the  histological  features  of  the  biopsies  showed
ntraepithelial  lymphocytosis.  The  ﬁndings  were  suggestive
f  lymphocytic  colitis.  He  started  treatment  with  budes-
nide  9  mg/day  with  good  symptomatic  improvement.  He
as  then  discharged  and  follow-up  was  made  in  clinic.
After  one  month,  the  patient  was  once  again  admit-
ed  in  our  Department  due  to  symptomatic  recurrence.  He
resented  a  total  of  15  kg  weight  loss.  Blood  tests  showed
ypokalemia  of  2.9  mmol/l,  hypomagnesemia  of  1.3  mmol/l
nd  hypoalbuminemia  of  2.3  g/dL.  Complete  blood  cell
ount  was  normal.  There  were  no  changes  in  his  D-Xylose
bsorption  test  as  well  as  fecal  pancreatic  elastase  and  stool
ultures.  Abdominal  CT  and  gastrointestinal  transit  showed
igniﬁcant  dilatation  of  the  small  bowel  but  no  stricture  or
tenosis  were  found.  An  endoscopic  ultrasound  showed  an
trophic  pancreas  with  a  normal  duct  of  Wirsung.  Celiac  dis-
ase  serology  (IgA  anti-transglutaminase,  anti-endomysial
nd  anti-gliadin  antibodies)  was  negative  and  the  genetic
est  for  HLA  DQ2/DQ8  was  positive.  An  endoscopy  was  also
erformed  and  duodenal  biopsies  showed  increased  intraep-
thelial  lymphocytes,  crypt  hyperplasia  and  villous  atrophy
grade  IIIC  according  to  the  modiﬁed  Marsh  classiﬁcation)
Fig.  1).  Meanwhile,  the  patient  showed  clinical  improve-
ent  and  he  was  discharge  with  the  diagnosis  of  celiac
isease.  His  eating  habits  were  changed  during  this  admis-
ion  and  he  started  a  gluten-free  diet.
After  approximately  45  days,  the  patient  was  admitted
ue  to  severe  recurrence  of  symptoms.  He  had  a  total  weight
oss  of  22  kg  then.  The  blood  tests  showed  a  prothrombin
ime  of  50%,  total  cholesterol  of  85  mg/dL,  triglycerides  of
3  mg/dL,  hypoalbuminemia  of  1.9  g/dL  and  transferrin  of
98  B.M.d.  Silva  et  al.
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oigure  1  Increased  number  of  intraepithelial  lymphocytes,
rypt  hyperplasia  and  complete  villous  atrophy.
84  mg/dL.  Stools  cultures  were  re-done  and  once  again  neg-
tive.  All  food  allergies  tests  turned  out  negative.  He  started
 hyperproteic  parenteral  nutrition  and  a  gluten-free  diet.
Due  to  a  sprue-like  enteropathy  with  negative  serology
or  celiac  disease,  we  decided  to  search  in  the  literature
or  similar  cases.  We  found  some  studies  describing  cases
f  olmesartan-associated  enteropathy.  Following  this,  olme-
artan  was  discontinued.  The  patient  had  an  impressive
utcome  and  all  clinical  signs  ceased  one  week  later.
A  close  follow-up  was  made  in  our  clinic  during  the  fol-
owing  two  months.  The  patient  presented  normal  bowel
abits  and  had  gain  weight,  although  he  claimed  to  have
eintroduced  gluten  to  his  diet  during  this  time.  Subse-
uently,  we  choose  to  let  the  patient  have  a  no  restriction
iet.  No  changes  were  noted  in  his  clinical  status  during  the
ollowing  consults.  Four  months  later,  the  patient  showed  a
eight  gain  of  20  kg  and  normal  bowel  habits.  A  histopatho-
ogical  review  was  made  and  duodenal  biopsies  showed  a
igniﬁcant  improvement  of  the  villous  architecture  (Fig.  2).
. Discussion
e  describe  a  case  of  severe  sprue-like  enteropathy  due  to
lmesartan.
The  exact  pathophysiology  underlying  remains  to  be
lucidated.  The  current  data  sustain  the  hypothesis  of  a
ell-mediated  immune  response3 based  on  the  presence  of
ntinuclear  antibodies  and  circulating  activated  T  cells,  and
o  the  fact  that  this  entity  presents  a  good  response  to
orticosteroid  and/or  immunosuppressive  treatment.4 The
athway  behind  the  inhibition  of  the  transforming  growth
actor  beta  has  also  been  considered.5 Nevertheless,  this  is
 question  that  requires  further  investigation.
Sprue  like  enteropathy  can  be  severe  in  up  to  50%  of  all
ases  and  sometimes  can  lead  to  perforation.3
Olmesartan-associated  enteropathy  may  mimic  celiac
isease.  However,  these  patients  do  not  respond  to  a  gluten-
ree  diet  and  celiac  disease  serology  is  negative.  In  our  study
LA  DQ2/DQ8  testing  was  positive.  Overall,  and  according
o  Rubio-Tapia  et  al.,  DQ2/DQ8  is  present  in  68%  of  patients
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eFigure  2  Signiﬁcant  improvement  of  the  villous
architecture.
ith  olmesartan-associated  enteropathy,  prevalence  higher
han  the  25--30%  expected  for  the  general  population,  sug-
esting  that  the  presence  of  HLA  DQ2/DQ8  may  increase
he  risk  of  immune-mediated  damage  in  these  patients.1,6
espite  its  association  with  DQ2/DQ8  genes,  olmesartan
oes  not  trigger  celiac  disease,  unlike  other  drugs  such  as
nterferon  or  ipilimumab.4
A  microscopic  colitis  could  also  be  a  potential  differen-
ial  diagnosis  of  this  entity  due  to  similar  histopathological
ndings.  Colonic  biopsies  showed  a  dense  lymphocyte
nﬁltration  and  a  thick  collagenous  subepithelial  layer.
owever,  the  patient  did  not  respond  to  treatment  with
orticosteroids.1,5,8
In  2012,  Pallav  et  al.  published  a  study  in  which  33%  of
atients  presented  a  non-speciﬁc  enteropathy  with  nega-
ive  serology.7 In  2013,  in  a  report  by  DeGaetani  et  al.,  14%
f  patients  presented  with  the  same  pathology  and  they
howed  that  this  number  could  have  been  increased  up  to
0%  if  an  olmesartan-associated  enteropathy  had  not  been
escribed  in  the  literature.8
Marisa  DeGaetani  et  al.  reported  a  study  with  72  patients
ith  villous  atrophy  and  negative  serology  for  celiac  disease.
he  realized  that  26%  of  her  cases  were  drug-associated,
eing  olmesartan  responsible  for  22.2%.  If  we  only  take
nto  consideration  the  data  regarding  the  drug-associated
nteropathy  cases,  we  can  conclude  that  84%  of  all  cases
ere  related  to  olmesartan  followed  by  mycophenolate
ofetil  (11%)  and  methotrexate  (5%).  This  study  shows  how
requent  this  entity  is  and  enhances  its  importance  when
utting  together  a  differential  diagnosis.8
In  this  clinical  case  we  did  not  reintroduce  olmesartan  to
onﬁrm  the  diagnosis  because  of  the  patient’s  severe  clini-
al  condition.  However,  whenever  the  patient  was  admitted,
lmesartan  was  discontinued  due  to  normal  arterial  pres-
ure.  Everytime  our  patient  was  discharged  olmesartan  was
eintroduced.  This  event  probably  justiﬁes  his  clinical  remis-
ion  and  relapses.  This  theory  is  conﬁrmed  by  Marthey
t  al.  In  this  speciﬁc  study  she  described  36  patients  with
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Villous atrophy, negative celiac serology and no response to gluten free diet
DQ2/DQ8
Drugs?
Olmesartan
Mycophenolate
Methotrexate
Azathioprine
Negative
CVID**
Autoimmune
enteropathy
Lymphoma
Tropical
sprue
Autoimmune disease
gut autoantibodies
Drugs-induced
enteropathy
CD* excluded
Discontinue drugs
Decrease plasma cell
in lamina propria
Duodenal
biopsy
Suspicion of
lymphoma
Antibiotics (Tetracycline)Travels to tropics?
Low vit. B12
Giardia stool testing
Hydrogen breath testing
Unclassified
sprue
Immunohistochemistry
T-cell receptor gen rearrangement
Increased plasma cells in
lamina propria
Decreased goblet cells
No increased intraepithelial
lymphocytes
Decreased serum levels
of at least two
immunologlobulin subtypes
Giardiasis
  CVID??
Bacterial
overgrowth
ID:  c
w
c
a
r
i
p
c
t
cFigure  3  *CD:  celiac  disease;  **CV
olmesartan-associated  enteropathy.  She  reported  10  cases
of  olmesartan  interruptions  which  were  followed  by  rein-
troductions  before  steroids  or  immunosuppressant  drugs.
Interruptions  were  followed  by  remissions  (9/10),  and  rein-
troductions  were  followed  by  relapses  (9/9).  Here  clinical
symptoms  occurred  28  months  after  the  ﬁrst  exposition  to
olmesartan.4 In  this  case  report,  our  patient  was  exposed  to
olmesartan  for  36  months  before  presenting  any  symptoms.
This  suggests  the  need  for  a  prolonged  exposure  time,  maybe
months  or  even  years,  until  the  onset  of  symptoms.
Overall,  cases  of  enteropathy  related  to  other
angiotensin  II  receptor  antagonists  seem  to  be  less  frequent
and  further  investigations  about  its  mechanism  of  action
is  still  required.  Until  now,  only  one  case  of  irbesartan-
associated  enteropathy  has  been  described.4 This  case
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fommon  variable  immunodeﬁciency.
as  very  similar  to  olmesartan-associated  enteropathy  in
linical  presentation  as  well  as  its  response  to  treatment
nd  drug  suspension.  Subsequently,  nowadays  it  is  not
ecommended  the  use  of  angiotensin  II  receptor  antagonists
n  patients  presenting  olmesartan-associated  enteropathy.
We  suggest  an  algorithm  to  help  making  a diagnosis  in
atients  who  present  villous  atrophy,  negative  serology  for
eliac  disease  and  no  response  to  gluten  free  diet  (Fig.  3).
In  conclusion,  it  is  expected  more  cases  like  this  in
he  future  due  to  high  use  of  olmesartan  in  current
linical  practice  for  treatment  of  hypertension.  Olmesartan-
ssociated  enteropathy  may  be  considered  as  a clinical
ntity,  and  should  be  included  in  the  differential  diagno-
is  of  a  sprue-like  enteropathy,  particularly  when  serology
or  celiac  disease  is  negative.
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